How will the HHS proposed rule changes to Medicare Part D and Medicaid drug rebate safe harbors impact pharmaceutical product net costs for PBMs?
Higher net costs after the implementation of the proposed rule
Lower net costs after the implementation of the proposed rule
No impact, net costs will be at the same levels as today
Vote
View Results
